|
⚲
|
| Keyboard |
| Camber Capital Management LP
✚
|
|
|---|---|
| CRD # | 298070 |
| SEC # | 801-113825 |
| CIK # | 0001444043 |
| AUM | |
| Employees | 8 (38% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 617-717-6600 |
| Address | 101 Huntington Avenue Boston, MA 02199 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (4/9/2025) [Brochure] |
|---|
Item 5: Fees and Compensation
A. Description
Camber bases its fees and performance compensation upon a percentage of assets under management
and upon performance. Clients typically pay Camber quarterly management fees no greater than 1.5%
per annum of the balance in such Client’s account or the net asset value of each investor’s investment in
a Client organized as a pooled investment vehicle. Clients also pay to Camber a performance fee equal to
no greater than twenty percent (20%) of the increase in net asset value of a Client’s account or of the
increase in the net asset value of an investor’s investment in a Client organized as a pooled investment
vehicle (after calculation and accrual of management fees) generally determined as of the last business
day of each fiscal year, subject to a high water mark. Such fees and compensation are currently not
negotiable.
B. Fee Billing
Management fees are deducted quarterly from each investor’s ' assets in advance. Any performance fee
is paid annually in arrears (or at the time of withdrawal if such withdrawal occurs prior to the end of a
fiscal year) from Clients' assets.
C. Other Fees and Expenses
Each Client managed by Camber pays or reimburses Camber, as the case may be, for all costs and expenses
related to its investments and its operations, including, without limitation, brokerage and other
transaction costs, clearing and settlement charges, interest and commitment fees on debit balances or
borrowings, borrowing charges on securities sold short, costs of any liability insurance obtained on behalf
of such Client, custody fees, costs of any litigation or investigation involving Client activities,
indemnification expenses, the management fees, the performance fee, consulting expenses, the fees and
expenses of professionals providing services to such Client, including legal, audit, accounting, tax and
administration services for Camber’s pooled investment vehicles as well as director services for Camber's
non-U.S. pooled investment vehicles that are organized as limited companies, any issue or transfer taxes
chargeable in connection with any securities transactions, any entity level taxes, regulatory costs, filing
and license fees, the costs of reporting and providing information and any extraordinary expenses.
Camber or one of its affiliates may elect from time to time to pay certain of a Client’s expenses in addition
to the organizational expenses, including, but not limited to, other operating expenses. Please refer to
Item 12 for more information about brokerage.
D. Fees in Advance
Clients pay management fees quarterly and in advance. Management fees are calculated based on the
balance in each Client's account or net asset value of an investor’s investment in a Client organized as a
pooled investment vehicle as of the beginning of each calendar quarter.
E. Securities Compensation
Not applicable.
Camber Capital Management LP 5 |
| Account Minimums and Types of Clients — Form ADV Part 2A (4/9/2025) [Brochure] |
|---|
Item 7: Types of Clients Description Camber currently provides investment advisory services and portfolio management on a discretionary basis for pooled investment vehicles. Account Minimums The Clients that Camber advises have minimum initial investments of $1,000,000, although when Camber is accepting new managed accounts or investors in a Client, Camber may accept lesser amounts in its sole discretion. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Zimmer Holdings Inc | 0.1 | ||
| Baxter International Inc | 0.1 | ||
| Humana Inc | 0.1 | ||
| CVS Caremark Corp | 0.1 | ||
| Globus Medical Inc | 0.0 | ||
| Icon PLC /Adr/ | 0.0 | ||
| Ascendis Pharma A/S | 0.0 | ||
| Merck & Co Inc | 0.0 | ||
| GlaxoSmithKline PLC | 0.0 | ||
| Pfizer Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Camber Capital Fund II LP | [2012-02-14] | 9.5 M | 23.1 M |
| Offered $9,472,572 · Filed 2022-06-24 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $1,000,000 · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Camber Capital Master Fund LP | [2012-02-14] | 1,205.9 M | 3,681.5 M |
| Filed 2025-06-04 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 3.7 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 3.7 |
| By Discretionary | ||
| Discretionary | 3 | 3.7 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 3.7 |
| By Non-United States Persons | ||
| Non-United States Persons | 1.4 | |
| United States Persons | 2.3 | |
| Total | 3 | 3.7 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Stephen Dubois | Executive Officer | 4 | 2 | |
| Camber Capital Management LLC | Promoter | 4 | 2 | |
| Camber Capital Partners LLC | Executive Officer, Promoter | 3 | 2 | |
| Camber Capital Management LP | Promoter | 3 | 2 | |
| Camber Capital Partners II LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001444043] | |
| 3 | [0001444043] | |
| 4 | [0001444043] | |
| SC 13D | [0001444043] | |
| SC 13G | [0001444043] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $3.3B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300DBP8IT426I0Z73 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
ZimVie Inc ZIMV
Common Stock
|
2024-08-02 | Sell | 525,000 | $17.71 | 9,297,750 |
|
AMAG Pharmaceuticals Inc AMAG
Common Stock
|
2020-10-01 | Sell | 4,390,000 | $13.57 | 59,572,300 |
|
AMAG Pharmaceuticals Inc AMAG
Common Stock
|
2019-08-09 | Buy | 26,600 | $8.94 | 237,804 |
|
AMAG Pharmaceuticals Inc AMAG
Common Stock
|
2019-08-09 | Buy | 3,400 | $9.18 | 31,212 |
|
AMAG Pharmaceuticals Inc AMAG
Common Stock
|
2019-08-07 | Buy | 4,000 | $7.58 | 30,320 |
|
AMAG Pharmaceuticals Inc AMAG
Common Stock
|
2019-08-07 | Buy | 301,000 | $7.79 | 2,344,790 |
|
AMAG Pharmaceuticals Inc AMAG
Common Stock
|
2019-08-07 | Buy | 50,000 | $7.74 | 387,000 |
|
Protalix BioTherapeutics Inc PLX
Common Stock
|
2016-12-02 | Sell | 2,500,000 | $0.32 | 800,000 |
|
Cardiovascular Systems Inc CSII
Common Stock
|
2016-09-20 | Sell | 57,000 | $23.54 | 1,341,780 |
|
Cardiovascular Systems Inc CSII
Common Stock
|
2016-09-19 | Sell | 1,043,000 | $23.25 | 24,249,750 |
|
Cardiovascular Systems Inc CSII
Common Stock
|
2016-02-23 | Buy | 250,000 | $7.55 | 1,887,500 |
|
Sequenom Inc SQNM
Common Stock
|
2016-01-04 | Buy | 75,000 | $1.59 | 119,250 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-31 | Buy | 395,435 | $1.64 | 648,513 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-30 | Buy | 195,000 | $1.59 | 310,050 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-15 | Buy | 20,000 | $1.41 | 28,200 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-14 | Buy | 20,000 | $1.26 | 25,200 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-14 | Buy | 428,000 | $1.30 | 556,400 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-10 | Buy | 253,565 | $1.36 | 344,848 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-09 | Buy | 213,000 | $1.32 | 281,160 |
|
Sequenom Inc SQNM
Common Stock
|
2015-12-08 | Buy | 325,000 | $1.24 | 403,000 |
| showing 20 of 32 most recent transactions | |||||